{"id":"20220426147","sourceId":"marketwatch","sourceName":"MarketWatch","providerName":"Dow Jones","title":"Pfizer, Valneva plan to move Lyme disease vaccine candidate into Phase 3 trial","publishedDate":"2022-04-26T06:59:00-05:00","body":[{"type":"p","contentObject":[{"type":"text","content":"\n  Pfizer Inc. (PFE) said Tuesday that an experimental Lyme disease vaccine it's developing with Valneva SE  will move into a Phase 3 clinical trial that includes children who are at least 5 years old, based on \"positive\" results among pediatric participants from the Phase 2 study. The Phase 3 trial is expected to begin in the third quarter. The companies said in a news release that the vaccine candidate was more immunogenic in pediatric participants compared with adults in the Phase 2 study. Pfizer's stock has declined 17.1% this year, while the broader S&P 500  is down 9.8%. ","gated":false}],"gated":false},{"type":"text","content":"\n","gated":false},{"type":"p","contentObject":[{"type":"text","content":"\n  -Jaimy Lee ","gated":false}],"gated":false},{"type":"text","content":"\n","gated":false},{"type":"pre","contentObject":[{"type":"text","content":"\n ","gated":false}],"gated":false},{"type":"text","content":"\n","gated":false},{"type":"p","contentObject":[{"type":"text","content":"\n  (END) Dow Jones Newswires","gated":false}],"gated":false},{"type":"text","content":"\n","gated":false},{"type":"p","contentObject":[{"type":"text","content":"\n  04-26-22 0759ET","gated":false}],"gated":false},{"type":"text","content":"\n\nCopyright (c) 2022 Dow Jones & Company, Inc.","gated":false}]}